{
  "Disease": [
    {"role": "user", "content": "Please identify the \"Disease\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Disease\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: In this retrospective single - centre analysis , patients with relapsed or refractory HL treated with gemcitabine 1 , 000 mg / m ( 2 ) day ( D ) 1 , D8 and D15 ; methylprednisolone 1 , 000 mg D1 - 5 ; and cisplatin 100 mg / m ( 2 ) D15 , every 28 days ( GEM - P ) were included .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| Relapsed or refractory Hodgkin's lymphoma (HL) |"},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Disease\" and present the valid entities as a Markdown table with one column \"Disease\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Disease |\n| --- |\n| Relapsed or refractory Hodgkin's lymphoma (HL) |"}
  ],
  "Chemical": [
    {"role": "user", "content": "Please identify the \"Chemical\" entities in the following paragraph. Please present the valid entities as a Markdown table with one column \"Chemical\". Make sure to present the entities precisely in the same words as in the original paragraph.\n\nParagraph: In this retrospective single - centre analysis , patients with relapsed or refractory HL treated with gemcitabine 1 , 000 mg / m ( 2 ) day ( D ) 1 , D8 and D15 ; methylprednisolone 1 , 000 mg D1 - 5 ; and cisplatin 100 mg / m ( 2 ) D15 , every 28 days ( GEM - P ) were included .\n\nLet's think step by step."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| gemcitabine 1,000 mg / m<sup>2</sup> |\n| methylprednisolone 1,000 mg |\n| cisplatin 100 mg / m<sup>2</sup> |\n\nIn this retrospective single-centre analysis, patients with relapsed or refractory HL were included who were treated with:\n\n1. gemcitabine: 1,000 mg / m<sup>2</sup> on days 1, 8, and 15\n2. methylprednisolone: 1,000 mg daily from day 1 to 5\n3. cisplatin: 100 mg / m<sup>2</sup> on day 15\n\nThis regimen was given every 28 days (GEM-P)."},
    {"role": "user", "content": "Please remove entities that do not clearly refer to \"Chemical\" and present the valid entities as a Markdown table with one column \"Chemical\".\n\nMake sure to present the entities precisely in the same words as in the original paragraph."},
    {"role": "assistant", "content": "| Chemical |\n| --- |\n| gemcitabine 1,000 mg / m<sup>2</sup> |\n| methylprednisolone 1,000 mg |\n| cisplatin 100 mg / m<sup>2</sup> |\n\nIn this retrospective single-centre analysis, patients with relapsed or refractory HL were included and treated with the following chemicals:\n\n1. gemcitabine: 1,000 mg / m<sup>2</sup> on days 1, 8, and 15\n2. methylprednisolone: 1,000 mg daily from day 1 to 5\n3. cisplatin: 100 mg / m<sup>2</sup> on day 15\n\nThese chemicals were administered every 28 days as part of the GEM-P regimen."}
  ]
}